“We are pleased to appoint David Bruce to the role of president and CEO,” said Dr. Ruediger Naumann-Etienne, lead independent director at IRIDEX. “David brings substantial experience leading successful commercial and market penetration strategies at several medical device companies, and he has been a member of IRIDEX’s Board of Directors for over a year. He is well prepared to expand worldwide sales and marketing execution for the Cyclo G6 Glaucoma Laser and Probe System and to build on IRIDEX’s retina laser position in the global market. We look forward to David’s leadership driving the company to significant growth.”
Bruce has been a member of IRIDEX’s board since April 2018 and has held several CEO and leadership positions in both public and private medical device growth-stage companies. He served as CEO and director of Arstasis, an arterial access device company, CEO and director of EP MedSystems, which was acquired by St. Jude Medical Inc., and interim CEO and director of Patient Safety Technologies. He was also general manager of the AcuNav Catheter Business for Siemens Medical Solutions, and chief operating officer for Catheter Robotics, a privately held, pre-commercial remote catheter systems company.
Bruce earned an MBA from the Wharton School at the University of Pennsylvania and a bachelor of science degree in mechanical engineering from the University of California, Berkeley.
“I am excited to lead IRIDEX in capitalizing on our MicroPulse therapy for glaucoma patients,” said Bruce. “This technology, with over 120,000 procedures performed by hundreds of ophthalmologists worldwide and a rapidly-expanding body of clinical data that demonstrate its efficacy, low risk and cost advantages for reduction of intraocular pressures, deserves a much greater role treating the large glaucoma patient population worldwide. Our business model combines proprietary laser systems with disposable delivery probes creating a significant growth and recurring revenue opportunity through broader adoption in the ophthalmology community. Coupling this with IRIDEX’s position in the retina laser market— with its own growth opportunities using MicroPulse technology— creates a platform for the creation of significant shareholder value. I am pleased to join the IRIDEX team to focus on growing the company’s revenue and achieving our value potential.”
Dr. Naumann-Etienne expressed his appreciation to outgoing CEO William M. Moore: “We thank Will for his leadership and contributions over the past six years in IRIDEX’s development and launch of this glaucoma therapy, positioning the company for the exciting growth opportunities ahead.”
IRIDEX Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.